Cerebral small vessel disease in deep penetrating arteries is a major cause of lacunar infarcts, white matter lesions and vascular cognitive impairment. Local cerebral blood flow in these small vessels is controlled by endothelial-derived nitric oxide, which exerts a primary vasodilator stimulus on vascular myocytes, via cytoplasmic cyclic GMP. Here, we investigated whether the cGMP-degrading enzyme phosphodiesterase-5 (PDE5) is present in small penetrating arteries in the deep subcortical white matter of older people. Frontal cortical tissue blocks were examined from donated brains of older people (n ¼ 42, 24 male: 18 female, median age 81, range: 59-100 years). PDE5, detected by immunohistochemical labeling, was graded as absent, sparse, or abundant in vascular cells within small arteries in subcortical white matter (vessel outer diameter: 20-100 mm). PDE5 labeling within arterial myocytes was detected in all cases. Degree of PDE5 expression (absent, sparse, or abundant) was not associated with age or with neuropathological diagnosis of small vessel disease. In conclusion, PDE5 is present in vascular myocytes within small penetrating arteries in older people. This is a potential molecular target for pharmacological interventions.
INTRODUCTION
Cerebral small vessel disease (SVD) is associated with reduced cerebral blood flow (CBF) in deep brain regions. SVD is the most common cause of white matter lesions (WML), lacunar infarcts and cerebral microbleeds, and a significant contributor to vascular cognitive impairment (VCI) (1, 2) . Nitric oxide (NO) produced by vascular endothelium plays crucial roles in regulating vascular tone and is a key regulator of CBF. Endothelial-derived NO has a vasorelaxant action in small arteries, stimulating guanylate cyclase activity in the cytoplasm of vascular myocytes. This leads to increased formation of the cytoplasmic messenger cyclic GMP (cGMP) and hence to vasodilation. The vasodilator effects of NO are curtailed by degradation of cytoplasmic cGMP by phosphodiesterase enzymes (such as PDE5) (3) . In some vascular beds, e.g. the corpus cavernosum of the erectile tissue, PDE5 is the main cGMP degrading enzyme (3) .
Reduced CBF is a well-established finding in SVD and in VCI (4) . Increasing blood flow in the vasculature of the deep white matter and deep gray nuclei is an attractive hypothesis for slowing progression of VCI-related pathology (5) . Pharmacological PDE5 inhibitors (such as sildenafil, Viagra) are now widely used clinically to treat erectile dysfunction or pulmonary hypertension. PDE5 blockade, prolonging the action of NO, would be a plausible strategy to increase local CBF in deep brain areas affected by SVD (6) . In this study, we aimed to identify whether PDE5 protein expression is present in small penetrating arteries in the brains of elderly humans and whether PDE5 related to the presence of SVD.
MATERIALS AND METHODS
We examined subcortical white matter tissue in a cohort of older people with documented neuropathological diagnosis of moderate-severe SVD (n ¼ 20) and aged control cases (n ¼ 22). See the and aged control cases were defined according to neuropathological criteria documented for all cases. The criteria are defined in Ref (1) . Briefly, hematoxylin and eosin sections were assessed by a registered neuropathologist. SVD was defined by vasculopathy-oriented criteria, including hyaline thickening of arteriolar walls; widened perivascular spaces; parenchymal changes considered to result from SVD (perivascular pallor of myelin staining, loosening with attenuation of nerve fibers with gliosis in white matter or loss of nerve cells and gliosis in deep gray matter) in one or more sections (1, 7), see Supplementary Data Methods.
All cases had minimal AD neuropathology (Braak stage II or less) (7, 8) . All donors were in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort (https://www.ndcn.ox.ac.uk/research/centre-preventionstroke-dementia/resources/optima-oxford-project-to-investigate-memory-and-ageing. Accessed December 10, 2018.). Tissue was harvested with postmortem delay <100 hours. This study had approval of the UK National Research Ethics Service. All tissue was donated following written informed consent by donors or next of kin.
Immunohistochemical labeling was performed as in our previous published work (7, 9) (Supplementary Data Methods). Methods for defining neuropathological grades of SVD severity, vessel sclerotic index, degree of PDE5 labeling, and radiological grade for white matter lesion load (derived from in-life CT scans) (10) are given in Supplementary Data Methods. Contingency tables were compared using Chi-squared tests. Differences between 2 experimental groups were tested using Mann-Whitney U-tests and between 3 or more groups using Kruskal-Wallis tests. p < 0.05 was considered significant.
RESULTS
Immunolabeling for PDE5 was detected in vascular myocytes of small arteries within deep subcortical white matter of older people (Fig. 1) . Some degree of myocyte PDE5 labeling was seen in all cases (n ¼ 42). Labeling was absent in neighboring sections treated identically with an irrelevant primary antibody (rabbit antisheep IgG; Fig. 1B) . Neighboring sections labeled with another PDE5 antibody (raised against a different immunogen) showed a qualitatively similar labeling pattern, with widespread labeling of vascular myocytes (Fig. 1C) . Vascular myocyte labeling was also seen in subcortical small arteries of young adults (age 18-40, n ¼ 3; example shown in Fig. 1D ).
As expected, immunolabeling for PDE5 was also seen in myocytes of small vessels within human corpus cavernosum and in Purkinje neurons within sections of cerebellar cortex (Supplementary Data Fig. S1 ). PDE5 labeling of vascular myocytic cells in brain vessels and in corpus cavernosum, as well as labeling of Purkinje neurons, were lost following immunodepletion of the primary antibody using the immunogenic peptide (Supplementary Data Fig. S1 ).
Older subjects with neuropathologically defined SVD (1) were compared with aged control subjects (Table) . The SVD group had lower cognitive scores (MMSE, CAMCOG) with higher incidence of clinical dementia than the control group (Table) . Neuropathological SVD severity score (8), radiological white matter lesion score (10), arterial sclerotic index (7), and incidence of cerebral atherosclerosis were all greater in the SVD group than in aged controls (Table) . The degree of brain vascular myocyte PDE5 immunolabeling was quantified using simple categorical grading (0 ¼ absent, 1 ¼ sparse, 2 ¼ abundant) for all small arteries within the size range of 20-100 mm. Among 42 cases examined, 5-10 vessels were scored for each case (median: 6 vessels per case, IQR 5.5, 7). The median PDE5 grade was "0" (absent) in 7 cases, "1" (sparse) in 26 cases, and "2" (abundant) in 9 cases. Within this cohort, median PDE5 grade did not significantly differ between SVD cases and aged controls (Supplementary Data Fig.  S2 ). Median PDE5 grade was not significantly associated with age at death, with neuropathological markers of SVD severity (average sclerotic index, neuropathological rating of SVD severity) or with severity of radiological white matter lesions (Supplementary Data Fig. S2 ). Regarding sclerotic index and PDE5 grade, we also performed sensitivity analyses at the individual vessel level and found no trend (not shown).
DISCUSSION
We explored PDE5 expression in vascular myocytes of small penetrating arteries within subcortical white matter of older people. We examined a well-characterized tissue cohort with detailed clinical and neuropathology data, selected for minimal Alzheimer disease (AD) pathology (8, 9) . We aimed to identify whether PDE5 protein expression was present in the brain vessels of this population of elderly humans and whether its presence correlated with the level of vascular disease. PDE5 immunoreactivity was present in vascular myocytes in all cases examined. The degree of positivity was not related to age or to neuropathological indicators of SVD severity (average sclerotic index for small arterial vessels, or neuropathological rating of SVD severity) (7, 8) .
Our findings accord with previous reports, demonstrating PDE5 mRNA and protein in brain tissue of humans and experimental animals (11) (12) (13) (14) . Western blot techniques detected PDE5 in lysates derived from meningeal and larger cerebral arteries of rodents and human patients (15) (16) (17) .
Our study has several limitations. First, as our group sizes are small, the statistical power of the study is limited. It may be that assessment of a larger cohort would detect modest differences between SVD and aged control groups (Supplementary Data Fig. S2 ). Second, we have deliberately excluded cases with AD pathology. Thus, we will miss possible interactions of SVD with AD vascular pathology. Third, we have not performed a comprehensive assessment of age-dependent PDE5 expression across all age ranges. Potent selective PDE5 inhibitors (e.g., sildenafil, tadalafil) are now widely used clinically to treat erectile dysfunction and pulmonary hypertension. PDE5 blockade is a possible strategy to increase local CBF in deep brain areas affected by SVD (6) . Clinical trials to examine effects of PDE5 inhibitors on brain perfusion are in progress within different patient groups (5, 18, 19) . This study demonstrates that the molecular target PDE5 is present in cerebral vascular myocytes, within the small arteries affected by SVD.
